H
Hiroshi Semba
Researcher at Fukuoka University
Publications - 45
Citations - 1028
Hiroshi Semba is an academic researcher from Fukuoka University. The author has contributed to research in topics: Lung cancer & Erlotinib. The author has an hindex of 13, co-authored 45 publications receiving 942 citations.
Papers
More filters
Journal ArticleDOI
Phase III Study of Docetaxel Compared With Vinorelbine in Elderly Patients With Advanced Non–Small-Cell Lung Cancer: Results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904)
Shinzoh Kudoh,Koji Takeda,Kazuhiko Nakagawa,Minoru Takada,Nobuyuki Katakami,Kaoru Matsui,Tetsu Shinkai,Toshiyuki Sawa,Isao Goto,Hiroshi Semba,Takashi Seto,Masahiko Ando,Taroh Satoh,Naruo Yoshimura,Shunichi Negoro,Masahiro Fukuoka +15 more
TL;DR: Docetaxel improved progression-free survival, response rate, and disease-related symptoms versus vinorelbine, and may be considered as an option in the standard treatment of elderly patients with advanced NSCLC.
Journal ArticleDOI
Phase III Study Comparing Second- and Third-Generation Regimens With Concurrent Thoracic Radiotherapy in Patients With Unresectable Stage III Non–Small-Cell Lung Cancer: West Japan Thoracic Oncology Group WJTOG0105
Nobuyuki Yamamoto,Kazuhiko Nakagawa,Yasumasa Nishimura,Kayoko Tsujino,Miyako Satouchi,Shinzoh Kudo,Toyoaki Hida,Masaaki Kawahara,Koji Takeda,Nobuyuki Katakami,Toshiyuki Sawa,Soichiro Yokota,Takashi Seto,Fumio Imamura,Hideo Saka,Yasuo Iwamoto,Hiroshi Semba,Yasutaka Chiba,Hisao Uejima,Masahiro Fukuoka +19 more
TL;DR: Arm C was equally efficacious and exhibited a more favorable toxicity profile among three arms and should be considered a standard regimen in the management of locally advanced unresectable NSCLC.
Journal ArticleDOI
Phase III trial of docetaxel plus gemcitabine versus docetaxel in second-line treatment for non-small-cell lung cancer: results of a Japan Clinical Oncology Group trial (JCOG0104)
Koji Takeda,S. Negoro,Tomohide Tamura,Yutaka Nishiwaki,S. Kudoh,Soichiro Yokota,Kaoru Matsui,Hiroshi Semba,Kazuhiko Nakagawa,Y. Takada,Masahiko Ando,Taro Shibata,Nagahiro Saijo +12 more
TL;DR: The incidence of ILD is higher for docetaxel combined with gemcitabine than for docETaxel alone in patients with previously treated NSCLC, still the standard second-line treatment forNSCLC.
Journal ArticleDOI
A phase II trial of gefitinib monotherapy in chemotherapy-naïve patients of 75 years or older with advanced non-small cell lung cancer.
Noriyuki Ebi,Hiroshi Semba,S. Tokunaga,Koichi Takayama,Hiroshi Wataya,Takashige Kuraki,Hidehiko Yamamoto,Shin j i Akamine,Isamu Okamoto,Yoichi Nakanishi +9 more
TL;DR: Gefitinib monotherapy is effective and relatively well tolerated in chemotherapy-naïve elderly patients with advanced NSCLC and has potential as a first-line therapeutic option in elderly patients without adenocarcinoma.
Journal ArticleDOI
Phase I and pharmacokinetic study of amrubicin, a synthetic 9-aminoanthracycline, in patients with refractory or relapsed lung cancer.
Isamu Okamoto,Isamu Okamoto,Akinobu Hamada,Yusuke Matsunaga,Ji Ichiro Sasaki,Shinji Fujii,Hideshi Uramoto,Haruhiko Yamagata,Ichiro Mori,Hiroto Kishi,Hiroshi Semba,Hideyuki Saito +11 more
TL;DR: The recommended phase II dose of amrubicin for patients with lung cancer refractory to standard chemotherapy is thus 35 mg/m2 once a day for three consecutive days every 3 weeks, with the specific dose-limiting toxicities being grade 4 neutropenia persisting for >4 days, febrile neutropania, or grade 3 arrhythmia in the three patients treated at this dose.